Generation Bio to Present at the TD Cowen 45th Annual Health Care Conference
CAMBRIDGE, Mass., Feb. 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025 at 9:10 a.m. ET in Boston.
A live webcast of the presentation will be available on the investor section of the company’s website at . A replay will be available there for 30 days following the event.
About Generation Bio
Generation Bio is a biotechnology company changing what's possible for people living with T cell-driven autoimmune diseases. The company is developing a new modality of therapeutics leveraging its T cell-selective cell-targeted lipid nanoparticle (ctLNP) to deliver siRNA in vivo, enabling modulation of T cell activity that causes inflammation and auto-reactive tissue destruction. By selectively modulating T cells that drive disease pathology, ctLNP-siRNA therapeutics could potently block target function with sequence-level specificity while sparing the broader immune system. This potent new modality is designed to reach targets that are poorly drugged by other approaches, opening a broad indication space of T cell-driven autoimmune diseases.
For more information, please visit .
Investors and Media Contact
Maren Killackey
Generation Bio
857-371-4638
